Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D06SBL
|
|||
Former ID |
DIB010382
|
|||
Drug Name |
MM-121
|
|||
Synonyms |
SAR-256212; EGFR antibodies (cancer), Merrimack; ErbB antibodies (cancer), Merrimack; MM-1x1 program (cancer), Merrimack; EGFR family tyrosine kinase receptor inhibitor (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis; ErbB3 tyrosine kinase receptor modulator (intravenous formulation/monoclonal antibody, cancer/NSCLC), Merrimack Pharmaceuticals/sanofi-aventis
Click to Show/Hide
|
|||
Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [2] | ||
Company |
Merrimack pharmaceuticals; sanofi us
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Erbb3 tyrosine kinase receptor (Erbb-3) | Target Info | Modulator | [3] |
KEGG Pathway | ErbB signaling pathway | |||
Calcium signaling pathway | ||||
Endocytosis | ||||
Proteoglycans in cancer | ||||
MicroRNAs in cancer | ||||
NetPath Pathway | TNFalpha Signaling Pathway | |||
Panther Pathway | Cadherin signaling pathway | |||
EGF receptor signaling pathway | ||||
Pathway Interaction Database | ErbB2/ErbB3 signaling events | |||
ErbB receptor signaling network | ||||
a6b1 and a6b4 Integrin signaling | ||||
WikiPathways | ErbB Signaling Pathway | |||
Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
Signaling Pathways in Glioblastoma | ||||
miR-targeted genes in muscle cell - TarBase | ||||
Heart Development |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01447706) A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 3 | Company report (Merrimack) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.